SCHEMBL21481817

SCHEMBL21481817

COC(=O)c1cccc2ccn(Cc3ccc(OC(F)(F)F)cc3)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 5/20 0.52
PTGDR Q13258 4/20 0.52
LMNA P02545 1/20 0.45
PTGER3 P43115 2/20 0.45
PTGER2 P43116 2/20 0.45
TBXA2R P21731 1/20 0.45
PTGER1 P34995 1/20 0.45
PTGFR P43088 1/20 0.45
TRPV1 Q8NER1 2/20 0.44
MRGPRX4 Q96LA9 1/20 0.44
EPHX2 P34913 2/20 0.43
PPARA Q07869 1/20 0.43
SERPINE1 P05121 1/20 0.43
GCGR P47871 1/20 0.41
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
CACNA1G O43497 1/20 0.41
CACNA1H O95180 1/20 0.41
CACNA1I Q9P0X4 1/20 0.41
AMPD2 Q01433 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29406596 0.87 PTGER4 (0.61) PTGER4PTGDRPTGER3PTGER2TBXA2R
SCHEMBL2111692 0.87 PTGER4 (0.61) PTGER4PTGDRPTGER3PTGER2TBXA2R
SCHEMBL1271452 0.84 PTGER4 (0.48) PTGER4PTGDRPTGER3PTGER2TBXA2R
SCHEMBL10019032 0.84 PTGER4 (0.49) PTGER4PTGDRPTGER3PTGER2TBXA2R
SCHEMBL989499 0.83 PTGER4 (0.44) PTGER4PTGDRPTGER3PTGER2TBXA2R
SCHEMBL12584167 0.83 PTGER4 (0.43) PTGER4PTGDRLMNAPTGER3PTGER2
SCHEMBL987514 0.82 PTGER4 (0.46) PTGER4PTGDRPTGER3PTGER2TBXA2R
SCHEMBL1137560 0.82 PTGER4 (0.47) PTGER4PTGDRPTGER3PTGER2MAPT
SCHEMBL28716996 0.81 PTGER4 (0.42) PTGER4PTGDRPTGER3PTGER2TBXA2R
SCHEMBL1748620 0.81 PTGER4 (0.62) PTGER4PTGDRPTGER3PTGER2TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 US disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 PTGER4 1/4885PTGDR 10/4885LMNA 1510/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 PTGER4 1/4885PTGDR 10/4885LMNA 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.